Viral Suppression and Discontinuation Rates have Improved in HIV Patients with Modern Antiretroviral Therapies

Patrick Hamel¹, Ashley M Yu², Sarwat Khan³, Daniel J Corsi³ and Curtis Cooper¹,²,³,⁴ *

¹School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario
²Doctor of Medicine Program, University of Ottawa, Ottawa, Ontario
³Ottawa Hospital Research Institute, Ottawa
⁴Department of Infectious Disease, The Ottawa Hospital, Ottawa, Ontario

Abstract

Objective: Rates and determinants of first-line antiretroviral (ARV) discontinuation or change in prescribed regimen were assessed between old (pre-2006) and modern (post-2006) era stratified by dosing frequency [once daily (QD) versus twice or more daily (BID+)].

Methods: A single-center retrospective cohort study was conducted. All adult HIV patients initiating ARVs from January 1996-November 2015 were included. Patients were stratified by old- or modern-era and by dosing frequency. The primary outcome was rate of ARV therapy discontinuation or change in initial regimen. The secondary outcome was reason for discontinuation.

Results: 1,127 patients were included from the old (n=621) and modern era (n=506). Modern-era patients were more likely to receive QD regimens (p<0.001) and had increased viral suppression at the last recorded testing than old-era patients (70.9% vs. 43.2%, p<0.001). Modern-era and QD patients had better adherence and treatment duration. Patients on integrase inhibitor (INSTI)- and NNRTI-based therapy had longer treatment durations and better ARV adherence. Risk factors for treatment switch or discontinuation included old-era therapy, IDU and PI+NRTI treatment.

Conclusion: In patients initiating first-line ARV, risk of discontinuation or regimen changes has diminished in the modern-era with QD, INSTI- or NNRTI-based regimens. More attention to high risk patients including IDU is advised in attempts to improve outcomes. These findings provide ‘real world’ support for current clinical practice guidelines.

Introduction

Since July 1996, highly active antiretroviral treatments (HAART) have represented standard of care for HIV management [1-3]. HAART has substantially reduced disease progression to AIDS, opportunistic infections, hospitalizations, and death [2]. However, the proportion of those diagnosed with HIV initiating antiretroviral therapy (ARV) is far from ideal [4,5]. Further, of those patients that do initiate therapy, high pill burdens, frequent dosing, and difficult side effects may contribute to poor treatment adherence [6,7].

It is estimated that 15-38% of HIV patients are non-adherent [2,4,8]. Barriers to ARV adherence include issues with scheduling, ARV safety concerns, stigma, and family responsibilities [9]. Identified risk factors for treatment discontinuation include young age (<40 years), higher HIV viral levels, AIDS, depression, injection drug use, African American ethnicity, higher burden of HIV symptoms, and diminished CD4 T cell counts response with ARV therapy [10-13].

Frequent dosing regimens for old-era HAART were major impediments to adherence. The development of single-tablet regimens, beginning in October 2006 with the regulatory approval of Atripla<sup>™</sup>, marked an important milestone in HIV therapy. Approval of Raltegravir in 2007 [14], Stridib<sup>™</sup> in 2012 [15] and Triumeq<sup>™</sup> in 2014 [16], allowed for utilization of low pill count regimens with reduced dosing frequencies and fewer side effects. Despite these advances, poor drug adherence remains an issue. Furthermore, little is known regarding risk factors for discontinuation of single dose ARV. Since many contributing factors affect patient and physician decisions to discontinue ARV, it remains uncertain as to whether the single dose, modern-era regimens have resulted in improved adherence and reduced ARV discontinuation compared to more complex regimens of the past.

We evaluated ARV discontinuation rates in old and modern-era first-line HIV regimens. Specifically, once daily (QD) and twice or more daily (BID+) dosing regimens were evaluated. We also assessed risk factors for discontinuation of the first prescribed ARV regimen in QD recipients.

Methods

A single-center retrospective non-concurrent cohort study of adult HIV patients was conducted at The Ottawa Hospital Immunodeficiency Clinic in Ottawa, Canada. Institutional Review Boards/Ethics Committees at the study site approved the performed study procedures prior to study initiation (REB 2004-032).

Keywords: HIV; Antiretrovirals; Adherence; QD dosing
All treatment-naive HIV positive patients initiating a first round of HAART from January 1995 to November 2015 were included assuming at least one month of medication was completed. Exclusion criteria included ARV post-exposure prophylaxis or atypical regimens (i.e., Fuzeon, hydroxyurea-based) or those with missing/aneedtal records. Patients were stratified by old and modern-era therapies, and by QD or BID+ dosing regimens. Old-era patients were defined as those initiating HAART before October 2006 and modern-era patients were those initiating HAART after this date.

The primary outcome focused on rates of ARV discontinuation and reasons for treatment interruption or switch as a function of treatment era. Secondary outcomes focused on the influence of dosing frequencies on these outcomes. The clinic database contained information on patient demographics, HIV exposure risk factors, alcohol and drug abuse history, country of origin, laboratory measures, therapy initiation and discontinuation dates as well as treatment adherence information. Reasons for discontinuing HAART were collected (Appendix 1). Blood work including HIV RNA and CD4 T cell counts were recorded at baseline/start of treatment and at 3, 6, 9, 12 and at 6 month intervals thereafter. ARV classes included, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs) and CCR5 antagonists [3].

Chi-Squared statistics were used for categorical variables, the T-test statistic for dates, and the Wilcoxon-Mann-Whitney test for laboratory measurements. Survival analysis methods were used to assess the risk of treatment discontinuation and HAART outcomes. Patients who died or discontinued therapy were treated as failure events while those continuing therapy were censored on the date of their most recent follow-up visit. Patients contributed person-time at risk for treatment discontinuation from the start of treatment until the time of discontinuation, last visit, death, or lost to follow-up. A sensitivity analysis was conducted where all lost to follow-up patients were considered to have discontinued treatment. Cox’s proportional hazard model was used to calculate hazard ratios (HR) for the multivariate analysis using SAS® statistics software (SAS Institute, Cary, NC). Tied data were taken into account using Breslow’s method.

The proportional hazard assumption was confirmed with the Kaplan-Meier and the Cox’s proportional hazard curve, and absence of interactions.

Results

A total of 1,127 patients receiving first-line HIV therapy were included in this analysis (Table 1). In both the old- and modern-era, the majority of patients were male (73%). By the later era the age distribution was older and more patients were non-White with increases in Black (28% to 36%) and Asian (1% to 4%) races indicating a change in patient demographics over time. More than 20% were HBV and/or HCV co-infected with a higher proportion of HIV mono-infection in the later era. Higher rates of IDU/crack cocaine use-history were noted in the pre-2006 era (p<0.001); HIV risk factors differed by era (p<0.001) and baseline CD4 cell counts >200 cells/µL were more prevalent in the post-2006 era (67% vs. 56%, p<0.001).

Treatment regimens and adherence status were stratified by era (Table 2). QD regimens were infrequently prescribed in the old-era (8%) compared to the modern-era (75%). The most frequently prescribed ARV regimen in the older era consisted of a PI+NRTI (56%); changing to a NRTI+NNRTI-based regimen in the modern era (46%), with a difference in class of ARV drug regimens across eras (p<0.001). Forty-two percent of modern-era patients remained on the

| Gender       | Old-Era* (n=621) | Modern-Era* (n=506) | Total (N=1127) | P-value* |
|--------------|------------------|---------------------|----------------|----------|
| n***         | n %              | n %                | N %            |          |
| Male         | 466 75.0         | 352 69.6           | 818 72.6       | 0.12     |
| Female       | 154 24.8         | 153 30.2           | 307 27.2       |          |
| Transgender  | 1 0.2            | 1 0.2              | 2 0.2          |          |

| Age          | <0.001           |
|--------------|------------------|
| 18-24 years  | 24 3.9           |
| 25-34 years  | 199 32.0         |
| 35-44 years  | 258 41.5         |
| 45+ years    | 140 22.5         |

| Race (n=861) | <0.001           |
|--------------|------------------|
| White        | 345 55.6         |
| Black        | 176 28.3         |
| Asian        | 8 1.3            |
| Aboriginal   | 15 2.4           |
| Hispanic     | 13 2.1           |
| Unknown      | 64 10.3          |

| Country of Birth | <0.001           |
|------------------|------------------|
| Canada           | 209 33.7         |
| Immigrant        | 314 50.6         |
| Unknown          | 98 15.8          |

| Co-infection Status | 0.005 |
|---------------------|-------|
| HIV only            | 468 75.5 |
| HCV+                | 114 18.4 |
| HBV+                | 32 5.2  |
| HCV+/HBV+           | 6 1.0   |

| History of Substance Abuse | 0.001 |
|----------------------------|-------|
| Alcohol/Drug Abuse History | 233 37.5 |
| Other risk factor          | 73 11.8 |

| HIV Risk Factors | <0.001 |
|------------------|-------|
| MSM              | 181 29.1 |
| IDU/Crack Cocaine| 126 20.3 |
| Transfusions/ Surgery | 32 5.2  |
| Origin from High Prevalence Area | 115 18.5 |
| Tattoo/Piercings/ Prison | 15 2.4  |
| Heterosexual sex  | 30 4.8  |
| Other risk factor | 73 11.8 |

| Baseline RNA (n=941) | 0.82 |
|----------------------|------|
| HIV RNA ≤ 100,000 copies/mL | 334 72.5 |
| HIV RNA >100,000 copies/mL  | 127 27.5 |

| CD4 (n=984) | <0.0001 |
|-------------|---------|
| ≤ 200 cells/µL | 224 44.4 |
| >200 cells/µL  | 281 55.6 |

**Old Era – Prior to October 2006; Modern-Era – after October 2006
***n’s less than the total sample size reflect missing data

Table 1: Baseline characteristics of patients included for analysis.

initially prescribed regimen at most recent visit compared to 3% during the older-era. Adherence to treatment regimen was improved in the modern era (91% vs 79%). Viral suppression surpassed 77% at last testing in the modern-era compared to 58% in the previous era.

Reasons for discontinuation stratified by treatment era and...
37

8.4

Treatment and regimen status stratified by ARV era.

| Dosing Frequency | Old-Era* (n=621) | Modern-Era* (n=506) | Total (N=1127) | p-value |
|------------------|------------------|---------------------|----------------|---------|
| n*** (%)         | n (%)            | N (%)               |                |         |
| **Dosing Frequency** |                   |                     |                |         |
| **QD**           | 52               | 379                 | 431            | 0.0001  |
| **BID+**         | 562              | 118                 | 680            | 38.2    |
| **Not recorded** | 7                | 9                   | 16             | 1.4     |
| **Drug Groups**  |                   |                     |                |         |
| **NRTI+PI**      | 348              | 146                 | 494            | 43.8    |
| **NRTI+NNRTI**   | 135              | 235                 | 370            | 32.8    |
| **NRTI+INSTI**   | 0                | 91                  | 91             | 8.1     |
| **Combination NRTI** | 69              | 17                  | 88             | 7.6     |
| **NNRTI+PI**     | 36               | 1                   | 37             | 3.3     |
| **Others/CCR5+NRTI+PI+INSTI** | 14        | 5                   | 19             | 1.7     |
| **PI Monotherapy** | 16              | 3                   | 19             | 1.7     |
| **Not recorded** | 3                | 8                   | 11             | 1       |
| **Treatment Status** |                   |                     |                |         |
| **On original regimen at last assessment** | 20               | 214                 | 234            | 20.8    |
| **LTFU/death**   | 50               | 27                  | 77             | 6.8     |
| **Changed initial ARV regimen** | 533           | 254                 | 787            | 69.8    |
| **Stopped ARV entirely** | 18           | 11                  | 29             | 2.6     |
| **Viral Load while on therapy (n=923)** |                   |                     |                |         |
| **Viral Suppression** | 268            | 358                 | 626            | 67.8    |
| **Viral failure** | 192              | 103                 | 295            | 32.0    |

**Dosing frequency are presented in Table 3. Most reasons for change or discontinuing the first prescribed regimen were similar in proportion between QD and BID+ regimens, although gastrointestinal symptoms and metabolic concerns were higher in the BID+ group. Overall discontinuation rates of initially prescribed HAART were greater in the early (89%) compared to the later era (53%, p<0.001). The most common reasons for treatment discontinuation/change in the entire cohort included intent to improve dosing regimen (17%), gastrointestinal side effects (9%), and neuropsychological side effects (7%). There were several differences observed between old-era and modern-era therapy discontinuation reasons including gastrointestinal disorders (p<0.001), viral breakthrough (p<0.001), metabolic disorder (p<0.001), and end of clinic study (p=0.007). When stratified by dosing frequency, there was a difference between total discontinuation rate between QD and BID+ regimens (p<0.001). There were differences between QD and BID+ treatment regimen discontinuation for reasons of gastrointestinal side effects (p=0.001), metabolic concerns (p<0.001), end of clinical study (p=0.04), viral breakthrough (p=0.003) and abnormal hematology results (p=0.04).

Adherence was improved in the QD group (91%) compared to the BID+ strata (79%) (p<0.001) (Table 4). Viral suppression was achieved in a greater frequency with QD dosing (76%) compared to BID+ (62%). Viral failure was lower among patients with QD dosing (24%) compared to BID+ (38%) (p<0.001); across both groups.

**Survival analysis**

The median treatment durations were shorter during the old-era [21 months (18-24) versus 37 (34-46), log-rank p<0.0001] and with BID+ dosing [24 months (20-26) versus 37 (30-48), log-rank p<0.0001] (Figure 1). Across ARV regimens, INSTI+NRTI [36 months (34-53)] and NNRTI + NRTI [35 months (29-46)] regimen recipients were observed to have lower treatment durations compared to PI + NRTI-containing regimen recipients [21 months (18-26), log-rank p<0.0001]. Crude analyses of several risk factors associated with HIV exposure (MSM, IDU, origin from a high-prevalence area) did not indicate a statistical difference in the likelihood of remaining on the initially prescribed ARV regimen (Log rank χ²=3.99 (2 d.f.); p=0.14), although the median duration of initial therapy was 17 months in IDU compared to 26 and 27 months in MSM and those having HIV originating from a high prevalence region, respectively.

**Correlates of time to treatment discontinuation**

In unadjusted analyses of time to treatment discontinuation, patients starting therapy in the old-era had an increased risk of discontinuing first line ARV compared with those starting after October 2006 [HR 1.5 (95% CI: 1.29, 1.74)], this attenuated but remained significant after adjusting for confounders [HR 1.35 (95% CI: 1.11, 1.63)] (Table 5). The risk of ARV discontinuation was also higher in those on BID+ regimens in unadjusted analyses (HR 1.4), although this effect was attenuated after multivariable adjustment and was not statistically significant at conventional levels (HR 1.04, (95% CI: 0.85-1.27), p=0.72) in the final model. Patients initiating INSTI+NRTI and NNRTI+NRTI regimens were less likely to discontinue first line therapy compared to patients on PI+NRTI regimens in unadjusted models. The effect of PI+NRTI (HR 1.19, (95% CI: 1.00-1.42) remained significant after adjustment for a series of covariates including age, sex, risk factors, viral co-infection, baseline laboratory data, race and immigrant status. The final multivariable model indicated that IDU/crack cocaine usage was associated with a 1.30 HR for discontinuation/switch (95% CI:
1.00-1.68, p=0.046) compared to other risk factors. IDU users were less likely to remain on their initially prescribed regimen (5.2% vs 11.4%, p=0.007) or switch in an attempt to improve their regimen (14.7% vs. 28.8%, p=0.002) compared to MSM. Immigrants were less likely to remain on their initially prescribed regimen (5.2% vs 11.4%, p=0.046) compared to Canadian-born. Those greater than 35 years of age were less likely to discontinue therapy compared to those aged 18-24 years.

**Sensitivity analysis**

A sensitivity analysis was conducted with all lost to follow-up patients (n=71) coded as discontinuing treatment rather than being censored. The same patterns of discontinuation were observed. The effects for era of starting therapy, dosing frequency, regimen type were diminished but remained statistically significant and clinically relevant. The median time to when half of the patients discontinued treatment in the old-era group with a HR of 1.5 (p<0.001). Compared with OD regimens, more frequently dosed regimens were associated with a HR of 1.4 (p<0.001). PI+NRTI regimens were associated with a HR of 1.3 (p<0.001) compared to other regimens.

**Discussion**

Our analysis identified that prescription of modern regimens has resulted in increased HIV viral suppression and lower HIV viral failure rates. Patients on QD regimens were significantly more adherent. Our observations indicate that ARV side effects and regimen improvements remain major reasons driving patient discontinuation of first-round therapy in the modern HAART era and are consistent with the findings of other groups [17-19]. The most common reasons for treatment switch or discontinuation were consistent over time and included change in regimen with the aim of improving the ARV regimen, gastrointestinal side effects, or neuropsychological complications. These results suggest that treatment discontinuation in the modern-era of ARV and challenges to drug adherence remain key clinical issues [20-23]. Nevertheless, the benefits of less frequent treatment dosing was demonstrated in this analysis as QD patients were more adherent than BID+ patients, were more likely to achieve viral suppression, and less likely to discontinue or switch their initially prescribed regimen due to viral failure [18,24-29]. These findings are highly relevant to informing clinicians in their attempts to retain patients on effective antiretroviral therapies.
Table 5: Unadjusted and adjusted hazard ratios and 95% confidence intervals from Cox proportional hazards model of correlates of treatment discontinuation.

| Era of therapy       | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| **Old-era**          | 1.50          | (1.29-1.74)       | <0.001  | 1.35        | (1.11-1.63)       | <0.001  |

| Dosing frequency     | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| **BID+**             | 1.43          | (1.23-1.67)       | <0.001  | 1.04        | (0.85-1.27)       | 0.72    |

| Regimen type         | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| **NNRTI+NRTI**       | 0.76          | (0.65-0.89)       | <0.001  | 0.94        | (0.77-1.15)       | 0.55    |
| PI+NRTI              | 1.33          | (1.16-1.52)       | <0.001  | 1.19        | (1.00-1.42)       | 0.048   |

| Risk factors         | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| MSM                  | 0.94          | (0.82-1.09)       | 0.41    | 1.21        | (0.96-1.52)       | 0.11    |
| IVDU/crack           | 1.13          | (0.92-1.39)       | 0.25    | 1.30        | (1.00-1.68)       | 0.046   |
| Transfusion, surgery | 1.00          | (0.74-1.35)       | 0.98    |             |                   |         |
| High prevalence region | 1.05       | (0.88-1.26)       | 0.58    | 1.29        | (1.01-1.66)       | 0.045   |
| Tattoo/Piercings/Prison | 0.88       | (0.60-1.30)       | 0.52    |             |                   |         |
| Heterosexual sex     | 1.03          | (0.85-1.24)       | 0.80    |             |                   |         |
| Other/multiple risk factors | 0.82 | (0.62-1.09)       | 0.18    |             |                   |         |

| Age and Gender       | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| Gender (female)      | 0.96          | (0.82-1.12)       | 0.60    | 0.92        | (0.77-1.10)       | 0.359   |
| Age 25-34y           | 1.17          | (1.01-1.36)       | 0.04    | 0.84        | (0.62-1.15)       | 0.277   |
| Age 35-44 y          | 0.83          | (0.72-0.95)       | 0.01    | 0.71        | (0.52-0.96)       | 0.026   |
| Age 45+              | 1.03          | (0.88-1.21)       | 0.72    | 0.82        | (0.60-1.13)       | 0.228   |

| Viral co-infection   | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| HIV/HCV+             | 1.02          | (0.85-1.24)       | 0.61    |             |                   |         |
| HIV/HBV+             | 1.10          | (0.80-1.51)       | 0.55    |             |                   |         |
| HIV/HBV/HCV+         | 1.11          | (0.56-1.44)       | 0.75    |             |                   |         |
| Baseline viral load (>100,000 cp/mL) | 1.07       | (0.91-1.27)       | 0.41    |             |                   |         |
| Baseline CD4 (>200 cells/µL) | 0.87    | (0.75-1.01)       | 0.07    |             |                   |         |

| Race/ethnicity (ref. White) | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| Black                      | 1.04          | (0.90-1.20)       | 0.62    | 0.96        | (0.71-1.29)       | 0.769   |
| Asian                      | 0.84          | (0.52-1.36)       | 0.49    | 0.75        | (0.44-1.27)       | 0.280   |
| Aboriginal                 | 0.81          | (0.49-1.36)       | 0.43    | 0.98        | (0.61-1.98)       | 0.946   |
| Hispanic                   | 1.12          | (0.73-1.73)       | 0.61    | 0.88        | (0.53-1.46)       | 0.620   |

| Country of Birth          | Unadjusted HR | 95% CI            | p-value | Adjusted HR | 95% CI            | p-value |
|----------------------------|---------------|-------------------|---------|-------------|-------------------|---------|
| Immigrant                 | 0.82          | (0.71-0.94)       | <0.001  | 0.67        | (0.50-0.90)       | 0.008   |
| Unknown                   | 1.59          | (1.27-2.00)       | <0.001  | 1.23        | (0.88-1.70)       | 0.224   |
therapy and are a critical component of the HIV cascade of care [30,31]. At a public health level, sustained HIV RNA suppression in individuals translates into reduced transmission within populations at risk for acute HIV infection [32].

Patient characteristics, coupled with the HIV drug composition create a complex decision tree for selecting a regimen that is likely to facilitate adherence and that is clinically effective. INSTI- and NNRTI-containing regimens are characterized by lower rates of discontinuation of first-line therapy thereby supporting the use of this ARV class as first line therapy [33]. Those on INSTI+NNRTI and NNRTI+NNRTI regimens in our clinic were adherent to treatment longer than those on PI+NNRTI therapies (Table 5 and Figure 1). This likely explains much of our findings pertaining to therapeutic success with INSTI- and NNRTI-based treatment.

Now that efficient drug components are available, the challenge is to improve adherence, reduce therapy discontinuation and maintain viral suppression over the long term by focusing on patient-specific characteristics associated with negative outcome. To this end, multiple risk factors for ARV discontinuation were evaluated. In our cohort, past or present injection drug users remained on initially prescribed therapy for a shorter period of time compared to all other HIV risk factor groups (Table 5) [20].

Several limitations related to this analysis are acknowledged. At the study design level, the retrospective nature of the analysis meant that not all variables of interest were available. Although effect modifiers and confounders were considered, missing data could have introduced bias into our multivariate analysis. There was a potential risk of bias since the baseline characteristics between old-era and modern-era strata were imbalanced in terms of race, country of origin, substance abuse history and HIV risk factors. Although both eras covered approximately the same duration of time, it is possible that a time bias may exist whereby patients in the modern-era group have yet to discontinue treatment. Prospective evaluations with close clinical and laboratory monitoring of new ARV for first and subsequent lines of therapies are important to provide further insights into the reasons for suboptimal adherence and treatment discontinuation, and predict long-term outcomes. Prospective clinical investigations in other HIV-infected groups, such as children, elderly, pregnant women and marginalized populations, would also provide relevant knowledge.

Acknowledgement

This work was conducted as part of PH’s masters of epidemiology training with the University of Ottawa. We are grateful to Drs Marie-Hélène Roy-Gagnon and Nicholas Birkett for guidance during the conduct of this analysis. We thank David Mackie, Stephanie Schoen and Christina Vaz for their assistance with this project. No author declares a conflict of interest.

References

1. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Temelli A, et al. (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312: 410-425.
2. AIDSinfo (2016) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. NIAID.
3. Vera J, Aragão P, Guimaraes M, Vaz Pinto I (2012) Benefits of ART simplification on adherence, clinical and economic outcomes. J Int AIDS Soc 15: 18064.
4. Klimarx PH, Mutasa-Apollo T (2013) Patching a leaky pipe: The cascade of HIV care. Curr Opin HIV AIDS 8: 59-64.
5. WHO, UNICEF, UNAIDS (2013) Global update on HIV treatment 2013: Results, impact and opportunities. WHO Report in partnership with UNICEF and UNAIDS. World Health Organization, Geneva.
6. Carter M (2016) Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe.
7. Stock J (2013) Integrase inhibitors - new challenges for the treatment of HIV-1 infections. Med Monatschr Pharm 36: 448-459.
8. Public Health Agency of Canada (2013) HIV and AIDS in Canada: Surveillance Report to December 31, 2013.
9. Genberg BL, Lee Y, Rognen WH, Wilson IB (2015) Four types of barriers to adherence of antiretroviral therapy are associated with decreased adherence over time. AIDS Behav 19: 85-92.
10. Adhieh-Grant L, Tarwater PM, Schneider MF, Anastos K, Cohen M, et al. (2005) Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 38: 500-503.
11. Kim TW, Palepu A, Cheng DM, Libman H, Saitz R, et al. (2007) Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care 19: 1039-1047.
12. Li X, Margolick JB, Conover CS, Badri S, Riddler SA, et al. (2005) Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 38: 320-328.
13. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, et al. (2004) Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: A prospective study. Clin Infect Dis 39: 1190-1198.
14. Hosein S (2007) Raltegravir approved in Canada. CATIE.
15. Hosein S (2012) Stridol (the Quad) approved in Canada. CATIE.
16. ViVi Healthcare (2014) ViVi Healthcare receives approval for Triumeq™ (dolutegravir/abacavir/lamivudine), in Canada - a new once-daily single-pill regimen for the treatment of HIV.
17. Hart E, Curtis H, Wilkins E, Johnson M (2007) National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naive patients. HIV Med 8: 186-191.
18. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE (2011) Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 5: 357-367.
19. Boldenmedhin B, Wabe NT (2012) The reason for regimen change among HIV/AIDS patients initiated on first line highly active antiretroviral therapy in Ethiopia. A Prospective study. Clin Infect Dis 45: 1377-1385.
20. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
21. Bae JW, Guyer W, Grimm K, Alitce FL (2011) Medication persistence in the treatment of HIV infection: A review of the literature and implications for future clinical care and research. AIDS 25: 279-290.
22. Collins SE, Grant PM, Shafter RW (2016) Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients. Drugs 76: 75-98.
23. Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, et al (2007) Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clin Infect Dis 45: 1377-1385.
24. Ahdieh-Grant L, Tarwater PM, Schneider MF, Anastos K, Cohen M, et al. (2005) Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 38: 500-503.
25. Astuti N, Maggiolo F (2014) Single-Tablet Regimens in HIV Therapy. Infect Dis Ther 3: 1-17.
26. Bangsberg DR, Ragland K, Monk A, Deeks SG (2010) A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24: 2835-2840.
27. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maas JF, et al. (2008) Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 9: 164-176.
28. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, et al. (2008) Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose
combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med 9: 667-672.

29. Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, et al. (2008) Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials 9: 73-82.

30. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ (2011) The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 52: 793-800.

31. Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, et al. (2013) Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med 173: 1337-1344.

32. UNAIDS (2014) 90-90-90 ambitious treatment target to help end the AIDS epidemic.

33. Mayer KH, Krakower DS1 (2016) Antiretrovirals for HIV treatment and prevention: The challenges of success. JAMA 316: 151-153.